FDA expands approved use of Stivarga to treat liver cancer - FDA Press Releases

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.

from Food and Drug Administration--Press Releases http://ift.tt/2oNn05F
via IFTTT